Trade

with

Synta Pharmaceuticals Inc
(NASDAQ: SNTA)
AdChoices
3.03
-0.06
-1.79%
After Hours :
-
-
-

Open

3.12

Previous Close

3.08

Volume (Avg)

1.58M (1.44M)

Day's Range

3.02-3.13

52Wk Range

2.62-7.22

Market Cap.

315.72M

Dividend Rate ( Yield )

-

Beta

2.62

Shares Outstanding

104.37M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 0

    • Net Income

    • -90.19M

    • Market Cap.

    • 315.72M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 2.62

    • Forward P/E

    • -3.09

    • Price/Sales

    • -

    • Price/Book Value

    • 4.27

    • Price/Cash flow

    • -2.94

      • EBITDA

      • -87.04M

      • Return on Capital %

      • -97.46

      • Return on Equity %

      • -169.09

      • Return on Assets %

      • -97.46

      • Book Value/Share

      • 0.71

      • Shares Outstanding

      • 104.37M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Buy
        • 1 Year Price Target

        • 27.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -0.98

        • Cashflow Estimate

        • -0.39

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -

            • 82.75

            • Pre-Tax Margin

            • -

            • 39.38

            • Net Profit Margin

            • -

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.13

              • 0.76

              • Current Ratio

              • 3.50

              • 2.92

              • Quick Ratio

              • 3.43

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.57

              • 2.21

              • Book Value/Share

              • 0.71

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -2.43

                • 188.68

                • P/E Ratio 5-Year High

                • -10.45

                • 634.30

                • P/E Ratio 5-Year Low

                • -2.24

                • 124.82

                • Price/Sales Ratio

                • -

                • 8.72

                • Price/Book Value

                • 3.89

                • 7.95

                • Price/Cash Flow Ratio

                • -2.94

                • 45.45

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -169.09

                        (-)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -97.46

                        (-48.10)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -121.99

                        (-)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • -

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -87.56M
                      Operating Margin
                      -
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -2.94
                      Ownership

                      Institutional Ownership

                      70.99%

                      Top 10 Institutions

                      64.52%

                      Mutual Fund Ownership

                      14.62%

                      Float

                      64.34%

                      5% / Insider Ownership

                      7.23%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Fidelity® Select Biotechnology Portfolio

                      •  

                        3,254,017

                      • 0.00

                      • 3.12

                      • Prudential Jennison Health Sciences

                      •  

                        2,599,873

                      • 0.00

                      • 2.49

                      • iShares Nasdaq Biotechnology

                      •  

                        1,395,087

                      • 3.08

                      • 1.34

                      • iShares Russell 2000 (AU)

                      •  

                        1,016,643

                      • -1.01

                      • 0.98

                      • Vanguard Total Stock Mkt Idx

                      •  

                        869,300

                      • 0.00

                      • 0.83

                      • Vanguard Extended Market Index Fund

                      •  

                        693,755

                      • 16.03

                      • 0.66

                      • Candriam Eqs L Biotechnology

                      •  

                        530,000

                      • 0.00

                      • 0.51

                      • iShares Russell 2000 Growth

                      •  

                        473,054

                      • 0.77

                      • 0.46

                      • Fidelity Advisor® Biotechnology Fund

                      •  

                        471,286

                      • 0.00

                      • 0.45

                      • Deutsche Global Small Cap Fund

                      •  

                        387,463

                      • 0.00

                      • 0.37

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Caxton Corp

                      •  

                        29,891,849

                      • +4.37%

                      • 29.51

                      • CxSynta LLC

                      •  

                        7,761,716

                      • 0.00%

                      • 7.44

                      • Fidelity Management and Research Company

                      •  

                        3,725,303

                      • -6.68%

                      • 3.68

                      • Jennison Associates LLC

                      •  

                        3,669,941

                      • -7.80%

                      • 3.62

                      • BlackRock Fund Advisors

                      •  

                        2,526,884

                      • +3.10%

                      • 2.49

                      • Vanguard Group, Inc.

                      •  

                        1,543,451

                      • -0.35%

                      • 1.52

                      • Goldman, Sachs & Co.

                      •  

                        760,931

                      • +4.05%

                      • 0.75

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Distressed

                      Style

                      Small Core

                      Synta Pharmaceuticals Inc was incorporated in Delware in March 2000 and commenced operations in July 2001. The Company is a biopharmaceutical company, engaged in discovering, developing and commercializing small molecule drugs to ext...moreend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Its drug candidate, ganetespib, is a next generation Hsp90 inhibitor in Phase 3 development for non-small cell lung cancer (NSCLC) and in development program, including clinical trials for breast cancer, ovarian cancer and acute myeloid leukemia. In addition, It is developing a unique, proprietary platform for enhanced delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Its drug candidates and preclinical c...moreompounds are small molecules that can be readily synthesized by processes that it has developed. Its patent portfolio has a total of 906 patents and patent applications worldwide. With respect to its Hsp90 inhibitor program, it has 112 issued U.S. and foreign patents, and 154 pending U.S. and foreign counterpart patent applications.lessless

                      Key People

                      Ms. Anne C. Whitaker

                      CEO/Director/President

                      Keith R. Gollust

                      Chairman of the Board/Director

                      Keith S. Ehrlich

                      CFO/Chief Accounting Officer/Vice President, Divisional

                      Wendy E. Rieder

                      General Counsel/Vice President, Divisional

                      Dr. Paul A. Friedman,M.D.

                      Director

                      • Synta Pharmaceuticals Inc

                      • 45 Hartwell Avenue

                      • Lexington, MA 02421

                      • USA.Map

                      • Phone: +1 781 274-8200

                      • Fax: +1 781 274-8228

                      • syntapharma.com

                      Incorporated

                      2000

                      Employees

                      134

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: